Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Xenon plans a virtual fireside chat at TD Cowen’s neuropsychiatry and epilepsy summit, with webcast details to be posted on its website.

Rhea-AI Summary

Xenon Pharmaceuticals (XENE) will present at the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit in a virtual fireside chat on Wednesday, September 23, from 2:00 to 2:25 pm ET.

Details and webcast access will be available in the Investors section of Xenon’s website, with replays posted after the event, and the company notes that the listed date and time are subject to change. Xenon highlights its lead molecule, azetukalner, a KV7 potassium channel opener in late-stage clinical development for epilepsy, major depressive disorder and bipolar depression, and mentions additional KV7 and NaV1.7 programs in Phase 1 for pain.

Key Terms

KV7 potassium channel opener, NaV1.7

2 terms

KV7 potassium channel opener technical

"azetukalner, is a novel, potent KV7 potassium channel opener"

A Kv7 potassium channel opener is a drug that helps certain cellular ‘gates’ called Kv7 channels stay open so potassium can flow out of cells, calming electrical activity in nerves and muscle. For investors, these compounds matter because they can form the basis of treatments for conditions driven by excessive electrical firing—like some seizures, pain, or heart rhythm disorders—so successful candidates can create new medical markets or reduce risks in drug pipelines.

NaV1.7 technical

"including KV7 and NaV1.7 programs in Phase 1 development"

NAV1.7 is a specific protein in nerve cells that helps transmit pain signals to the brain; think of it as a gatekeeper that opens and closes to let electrical messages through. Investors watch drugs that block or modify NAV1.7 because successful therapies could relieve chronic pain without opioids, creating large market opportunities, while clinical setbacks or safety issues can sharply affect a company's valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:

• TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET

Details about the presentation, including webcast information, can be found on the Investors section of Xenon's website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc. 

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K_V7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K_V7 and Na_V1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner. 

Contacts: 

For Investors:
Laura Perry/Emily Huang
Argot Partners
Xenon@argotpartners.com

For Media:  
Colleen Alabiso  
Senior Vice President, Corporate Affairs  
media@xenon-pharma.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Where can investors find details and access the Xenon webcast?

Details about the presentation, including webcast information, can be found in the Investors section of Xenon’s website. When available, the webcast will also be posted there for replay following the event.

Can the date or time of Xenon’s TD Cowen fireside chat change?

The company states that the listed date and time for the virtual fireside chat are subject to change, so attendees should check for updates on Xenon’s website.